6956results about "Granular delivery" patented technology

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry 10 powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

Disclosed is a needle-free applicator that is suitable for administering a solid, amorphous, mono-particulate powder composition into a body cavity of a human patient, which cavity includes a mucosal surface, wherein the applicator comprises:(i) an opaque reservoir comprising said powder composition;(ii) an optional actuating means for generating a force upon actuation of the device by a user; and(iii)a dispensing means through which, following said actuation, said powder composition may be dispensed,wherein said powder composition comprises a pharmacologically-effective dosage amount of an adrenergic receptor modulator, or a pharmaceutically-acceptable salt thereof, encapsulated in an amorphous state along with a pharmaceutically-acceptable carrier material; andwhich powder composition is less than about 4% chemically degraded after storage for:(a) at least about 3 months at 40° C. and 75% relative humidity; and / or(b) at least about 18 months at below about 30° C.; and / or(c) at least about 18 hours at above about 1 million lux of UV light.

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

To inhibit delayed dissolution of a macitentan-containing preparation after being kept under open conditions prone to humidity, and to suppress the formation of macitentan analogues.SOLUTION: According to one embodiment of the present invention, there is provided a macitentan-containing preparation comprising granules containing macitentan and an additive other than the granules, wherein the granules contain at least one kind of a disintegrant selected from the group consisting of low-substituted hydroxypropyl cellulose, croscarmellose sodium, carmellose, and calcium carmellose.SELECTED DRAWING: None

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The invention belongs to the technical field of medicines, and provides a cassia twig granular preparation as well as a preparation method and a product thereof. The cassia twig granule preparation is prepared from the following components in parts by weight: 35 to 50 parts of cassia twig granule extract dry paste and 50 to 105 parts of auxiliary materials, the auxiliary materials comprise lactose, beta-cyclodextrin and derivatives thereof, and citric acid. According to the invention, beta-cyclodextrin and derivatives thereof are used for replacing dextrin as an auxiliary material in the cassia twig granules, so that the interference problem of dextrin in drug detection is avoided, the formability, solubility and hygroscopicity of the cassia twig granule preparation are ensured, the stability of the preparation is improved, and the comprehensive performance is excellent.

The invention relates to a method for controlling a continuous granulation and drying process, in which a model takes into account a combination of granulation by means of a granulator and subsequent drying by means of a dryer, by means of which control parameters or predictive recipe parameters are ascertained as a function of state parameters of the plant; and / or wherein the model has a static part, by means of which a reference value for the respective control parameter or predicted recipe parameter is determined by means of the state parameter, and the model has a dynamic part, by means of which the reference value is optimized by means of prediction.

The invention provides particles, compositions including the particles, and methods of making the particles using electrospray. In certain embodiments, the particles allow for high concentrations of a therapeutic or diagnostic agent to be delivered at low viscosity. Particles may also exhibit beneficial properties with respect to stability.

The present disclosure provides a method of treating a symptom or preventing a symptom of generalized anxiety disorder comprising administering an orally disintegrating tablet comprising LSD, or a salt thereof, to a subject in need thereof.

A method of producing a cannabinoid nanoparticle carrier composition for administration to a human and thereafter producing a consumable food product including the cannabinoid nanoparticle emulsification. The cannabinoid nanoparticle carrier composition is combined with a particulate food product, herb or spice, sugar, salt, or particulate preservative, mixed into a slurry or suspension, dried, and then ground to a size suitable for human consumption.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I):tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

The present invention relates to ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system comprising gas microbubbles, emulsion microdroplets and clusters thereof. Thus, the present invention relates to a cluster composition and a pharmaceutical composition, and their use for delivery of therapeutic agents and as a contrast agent for ultrasound imaging. It further relates to methods for delivering such therapeutic agents and to the use of said compositions.

The invention relates to hydrogel loaded with oxygen self-producing nanoparticles as well as a preparation method and application of the hydrogel. The preparation method comprises the following steps: 1, taking cross-linked methacrylamide silk fibroin and hyaluronic acid modified by arginine-glycine-aspartic acid peptide as base materials, and loading self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG, and the self-oxygen-producing nano particles CaO2 (at) PVP (at) Cu-EGCG are prepared by coating Cu-EGCG on calcium peroxide nano particles modified by PVP modified polyvinylpyrrolidone. The hydrogel can improve energy metabolism and regulate immune environment through dual mechanisms, realizes efficient promotion of myocardial repair, and provides a new strategy and thought for tissue regeneration and functional recovery after myocardial infarction.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a synthetic nicotine composition and a preparation method thereof. The nicotine buccal film agent disclosed by the invention is prepared from the following components in parts by weight: 2 to 4 parts of nicotine clathrate compound powder, 0.2 to 0.6 part of phosphatidic acid, 0.1 to 0.3 part of tannic acid, 0.1 to 0.2 part of sodium ascorbate, 0.04 to 0.06 part of tocopherol, 0.01 to 0.02 part of ethylene diamine tetraacetic acid, 2 to 4 parts of povidone and 40 to 80 parts of absolute ethyl alcohol. The synthesized nicotine composition prepared by the invention can effectively relieve the phenomenon that the faster the nicotine is released, the stronger the bitter taste is. Meanwhile, in a high-temperature and high-humidity environment, the stability of nicotine can be effectively maintained, and the oxidation half-life period of nicotine is prolonged.

The invention provides a metal polyphenol network coated self-assembled nano-drug as well as a preparation method and application thereof, and belongs to the technical field of nano-drugs. The self-assembled nano-drug provided by the invention is of an organic-inorganic hybrid core-shell nano-structure; the core of the organic-inorganic hybrid core-shell nano structure is BC NPs; the BC NPs is formed by self-assembly of BBR (Boron Butadiene Rubber) and Cur (Carbon); a shell layer of the organic-inorganic hybrid core-shell nanostructure is a dynamic cross-linked network formed by self-assembly of metal ions and polyphenol through coordination. Metal ions and polyphenol are self-assembled through coordination to form a dynamic cross-linked network, and the dynamic cross-linked network coats the outer layer of the BC NPs nano-particles, so that the BC NPs nano-particles have good biocompatibility and biological safety; and the self-assembled nano-drug shows an obviously enhanced antibacterial effect under the combined treatment of NIR and H2O2.

The invention discloses a traditional Chinese medicine composition with the effects of benefiting qi, nourishing blood, invigorating the spleen and tonifying the kidney and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: cistanche, ginseng, American ginseng, astragalus membranaceus, medlar, rhizoma polygonati, oyster peptide, angelica sinensis, radix rehmanniae preparata, donkey-hide gelatin, fructus amomi, pericarpium citri reticulatae, hawthorn, folium cortex eucommiae, radix puerariae, liquorice and the like. The preparation method comprises the following steps: respectively crushing the medicinal materials, dissolving the colla corii asini, mixing, adding water, granulating and the like. The composition can be prepared into various dosage forms such as granules, capsules, tablets, oral liquid and the like. Experiments show that the traditional Chinese medicine composition can effectively improve the symptoms of deficiency of qi and blood (increasing erythrocyte count and hemoglobin content), weakness of spleen and stomach (increasing body weight and improving pepsin activity) and kidney deficiency (reducing creatinine and urea nitrogen content and improving SOD activity), and acute toxicity experiments show that the toxicity is slightly reversible under high dosage, and the safety is good under therapeutic dosage. The traditional Chinese medicine composition has potential application value in the aspect of preparing medicines for benefiting qi, nourishing blood, invigorating spleen and tonifying kidney.

The invention belongs to the technical field of genetic engineering and biological medicine, and particularly discloses a cascade response type nano-particle with a microenvironment remodeling function and a preparation method and application of the cascade response type nano-particle. The nanoparticle provided by the invention adopts a bionic hybrid membrane engineering strategy: an inner core is formed by loading an exosome inhibitor on a nano material, and the surface is covalently coupled with M2 type macrophage specific targeting peptide; the outer layer coats a macrophage membrane and active oxygen response type liposome composite membrane layer through a co-extrusion technology, and is loaded with a TLR agonist. Animal experiments show that after being injected through caudal vein, the nano-particles are enriched at a tumor site in a targeted manner through homing receptors such as membrane surface integrin alpha4beta1 and the like, and outer membrane cracking is triggered in a high-ROS tumor microenvironment, so that space-time controlled release of a TLR agonist and targeted phagocytosis of an exosome inhibitor by macrophages guided by a targeted peptide are realized. The anti-tumor synergistic effect is achieved through multiple regulation and control mechanisms, and an effective treatment strategy is provided for tumor immunotherapy.

The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and one or more ginseng-derived compounds or a ginseng extract; and / or one of more notoginseng-derived compounds or a notoginseng extract. The invention also relates to uses of such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for non-therapeutic uses.

The invention discloses nucleic acid nano microspheres as well as a preparation method and application thereof, and belongs to the technical field of nano delivery. The preparation method comprises the following steps: carrying out first mixing on nucleic acid and part of water, and carrying out pretreatment and curing to form nucleic acid semi-solid gel; melting the nucleic acid semi-solid gel at 45-80 DEG C, and adjusting the pH value to 4-6 to form a phase A; carrying out second mixing on the spermidine-containing plant extract and the remaining water, and adjusting the pH value to 4-6 to form a phase B; and carrying out third mixing on the phase A, the phase B and an auxiliary agent to form the nucleic acid nano-microsphere, the nucleic acid nano-microsphere is prepared from the following components in percentage by mass: 0.5 to 8 percent of nucleic acid, 0.1 to 7.5 percent of a plant extract containing spermidine, 0 to 6 percent of an auxiliary agent and 78.5 to 99.4 percent of water, the mass ratio of the nucleic acid to the plant extract containing spermidine is (1-10): 1. The nucleic acid nano-microsphere has improved transdermal effect and stability, and can be used for transdermal drug delivery.

The invention provides a mesenchymal stem cell preparation for promoting knee joint repair as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: loading transforming growth factor-beta1 and interleukin-6 on chitosan microspheres, then preparing a chitosan-oxidized starch-carboxymethyl-beta-cyclodextrin bracket loaded with sustained release microspheres, loading luteolin and quercetin, carrying out mixed culture with mesenchymal stem cells, adding a traditional Chinese medicine extract, and carrying out freeze-drying to obtain the luteolin-quercetin-modified mesenchymal stem cells. The mesenchymal stem cell preparation for promoting knee joint repair is prepared. The preparation method of the carbon anode plate for fluorine preparation is simple, the generation of polarization of the carbon anode plate is prevented, and the carbon anode plate has the advantages of low porosity, low ash content, high mechanical strength, high volume density, obviously prolonged service life, low resistivity and the like, and has a wide application prospect.

The present disclosure relates to methods that enable the continuous formation of droplets and dehydration of droplets to provide pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled continuous droplet formation and dehydration that produce circular particles having low internal void spaces comprising bioactive therapeutic biologies.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The invention belongs to the field of pharmaceutical preparations, and relates to a brexpiprazole long-acting microsphere and a preparation method thereof, and the preparation method comprises the following steps: (1) dissolving brexpiprazole and a degradable polymer in an organic solvent to obtain a drug-containing polymer solution as an oil phase; (2) mixing the drug-containing polymer solution with a polyvinyl alcohol solution through a microfluidic technology to obtain an oil-in-water emulsion; and (3) under a stirring condition, carrying out curing, washing and freeze drying on the oil-in-water type emulsion to obtain the brexpiprazole long-acting microspheres. By adjusting the volatilization stirring time when the O / W primary emulsion is formed, the final in-vitro release rate of the microspheres is adjusted, and the microspheres which are free of burst release and hysteresis period and are slowly released can be screened out. The brexpiprazole long-acting microsphere provided by the invention is simple in preparation process, easy to industrially amplify, high in encapsulation efficiency, large in drug loading capacity, uniform in microsphere particle size distribution, round in shape, good in flowability and good in needle passing property, is easier to inject, has an obvious slow release effect, and can be used for reducing the fluctuation of blood concentration and effectively improving the compliance of psychiatric patients.